RMFCX | TRCVX | RMFCX / TRCVX | |
Total Expense Ratio | 0.91 | 0.30 | 303% |
Annual Report Gross Expense Ratio | 0.91 | 0.30 | 303% |
Fund Existence | 23 years | 23 years | - |
Gain YTD | 13.689 | 10.929 | 125% |
Front Load | N/A | N/A | - |
Min. Initial Investment | 250 | 0 | - |
Min. Initial Investment IRA | N/A | N/A | - |
Net Assets | 111B | 11.4B | 974% |
Annual Yield % from dividends | 1.20 | 1.52 | 79% |
Returns for 1 year | 4.96 | 5.75 | 86% |
Returns for 3 years | 38.79 | 39.85 | 97% |
Returns for 5 years | 57.10 | 64.70 | 88% |
Returns for 10 years | 91.18 | 87.05 | 105% |
1 Day | |||
---|---|---|---|
ETFs / NAME | Price $ | Chg $ | Chg % |
RSMR | 21.44 | 0.09 | +0.40% |
FT Vest U.S. Equity Equal Weight Buffer ETF - March | |||
JPI | 20.68 | N/A | N/A |
Nuveen Preferred Securities & Income Opportunities Fund | |||
NPFI | 26.39 | N/A | -0.02% |
Nuveen Preferred and Income ETF | |||
WDNA | 17.32 | -0.23 | -1.34% |
WisdomTree BioRevolution ETF | |||
ARKG | 31.00 | -1.08 | -3.37% |
ARK Genomic Revolution ETF |